Strattera

Generic Name: Strattera

What is Strattera?

Some cases presented with features resembling neuroleptic malignant syndrome. In extensive metabolizers EMsinhibitors of CYP2D6 e. In EM individuals treated with paroxetine or fluoxetine, the AUC of atomoxetine is approximately 6-to 8-fold and Css, max is about 3-to 4-fold greater than atomoxetine alone.

In vitro studies suggest that coadministration of cytochrome P450 inhibitors to PMs will not increase the plasma concentrations of atomoxetine. Because of possible effects on blood pressure, STRATTERA should be used cautiously with antihypertensive drugs and pressor agents e. STRATTERA should be administered with caution to patients being treated with systemically-administered oral or intravenous albuterol or other beta2 agonists because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.

Albuterol 600 mcg iv over 2 hours induced increases in heart rate and blood pressure. These effects were potentiated by atomoxetine 60 mg BID for 5 days and were most marked after the initial coadministration of albuterol and atomoxetine.

However, these effects on heart rate and blood pressure were not seen in another study after the coadministration with inhaled dose of albuterol 200-800 mcg and atomoxetine 80 mg QD for 5 days in 21 healthy Asian subjects who were excluded for poor metabolizer status. Atomoxetine did not cause clinically important inhibition or induction of cytochrome P450 enzymes, including CYP1A2, CYP3A, CYP2D6, and CYP2C9.

No dose adjustment is recommended for drugs metabolized by CYP3A. Coadministration of STRATTERA 40 or 60 mg BID for 13 days with desipramine, a model compound for CYP2D6 metabolized drugs single dose of 50 mgdid not alter the pharmacokinetics of desipramine.

Concomitant Use Of Potent CYP2D6 Inhibitors Or Use In patients Who Are Known To Be CYP2D6 PMs Atomoxetine is primarily metabolized by the CYP2D6 pathway to 4-hydroxyatomoxetine. General Information Physicians should instruct their patients to read the Medication Guide before starting therapy with STRATTERA and to reread it each time the prescription is renewed. Suicide Risk Patients, their families, and their caregivers should be encouraged to be alert to the emergence of anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia psychomotor restlessnesshypomania, mania, other unusual changes in behavior, depression, and suicidal ideation, especially early during STRATTERA treatment and when the dose is adjusted.

Severe Liver Injury Patients initiating STRATTERA should be cautioned that severe liver injury may develop. Aggression Or Hostility Patients should be instructed to call their doctor as soon as possible should they notice an increase in aggression or hostility.

Ocular Irritant STRATTERA is an ocular irritant. Drug-Drug Interaction Patients should be instructed to consult a physician if they are taking or plan to take any prescription or over-thecounter medicines, dietary supplements, or herbal remedies. Pregnancy Patients should be instructed to consult a physician if they are nursing, pregnant, or thinking of becoming pregnant while taking STRATTERA. Food Patients may take STRATTERA with or without food. Missed Dose If patients miss a dose, they should be instructed to take it as soon as possible, but should not take more than the prescribed total daily amount of STRATTERA in any 24-hour period.

Interference With Psychomotor Performance Patients should be instructed to use caution when driving a car or operating hazardous machinery until they are reasonably certain that their performance is not affected by atomoxetine.

How should I take Strattera?

Drug interactions occur frequently. Get facts about the types of drug interactions, what substances or other things that may interact with drugs such as OTC drug and prescription drugs, vitamins, food s grapefruitand laboratory tests. Find out how to protect yourself from potential drug interactions.

Learn daily living tips for adult ADHD Attention Deficit Hyperactivity Disorder. If you have ADHD or you just need to get yourself and your family organized, use these helpful tips to make your day flow smoothly.

Vyvanse and Strattera are both used in the treatment of attention deficit hyperactivity disorder ADHD.

What should I avoid while taking Strattera?

The mean final dose of STRATTERA was approximately 1. ADHD symptoms were statistically significantly improved on STRATTERA compared with placebo, as measured on the ADHDRS scale. This study shows that STRATTERA is effective when administered once daily in the morning. In both studies, ADHD symptoms statistically significantly improved more on STRATTERA than on placebo, as measured on the ADHDRS scale. There was not sufficient exposure of ethnic groups other than Caucasian to allow exploration of differences in these subgroups.

The effectiveness of STRATTERA in the maintenance treatment of ADHD was established in an outpatient study of children and adolescents ages 6-15 years. Patients meeting DSM-IV criteria for ADHD who showed continuous response for about 4 weeks during an initial 10 week open-label treatment phase with STRATTERA 1.

Strattera side effects

STRATTERA was administered to 5382 children or adolescent patients with ADHD and 1007 adults with ADHD in clinical studies. During the ADHD clinical trials, 1625 children and adolescent patients were treated for longer than 1 year and 2529 children and adolescent patients were treated for over 6 months. Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In acute child and adolescent placebo-controlled trials, 3. For all studies, including open-label and long-term studies6.

Results were similar in the BID and the QD trial except as shown in Table 3, which shows both BID and QD results for selected adverse reactions based on statistically significant Breslow-Day tests. The following reactions did not meet this criterion but were reported by more atomoxetine-treated patients than placebo-treated patients and are possibly related to atomoxetine treatment: blood pressure increased, early morning awakening terminal insomniaflushing, mydriasis, sinus tachycardia, asthenia, palpitations, mood swings, constipation, and dyspepsia.

Common Strattera ide effects may include:

  • Children should have their height and weight checked often while taking STRATTERA.

  • The treatment is equally varied, combining parental training techniques, classroom teaching styles and medications to manage these children.

  • The psychiatrist and psychologist told us that the Clonadine and Zoloft would calm him because the Strattera wasn't really working, but yet they wanted to keep our child on the Strattera.

  • Do not include any personal information or links in your review.

Pay close attention to your child whenever STRATTERA is started or its dose is changed. If you notice an increase in aggression or hostility since taking this medication, you should call your doctor as soon as possible. Tell your doctor if you experience a seizure, fit or convulsion. If you already suffer from seizures, fits or convulsions, tell your doctor if they seem to increase in frequency.

More about Strattera

Consumer resources

Other brands:Buy family pack online

Professional resources

Where can I get more information?

  • Researchers don't know exactly how it works for ADHD, but it increases norepinephrine activity in the brain, which affects attention and behavior.

  • Find your local NAMI Select State Your State Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware District of Columbia Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Puerto Rico Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virgin Islands Virginia Washington West Virginia Wisconsin Wyoming Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware District of Columbia Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Mass Join NAMI Inspire others with your message of hope.